Jennifer Buell - 02 Jan 2026 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Reporting relationship: Chief Executive Officer
Issuer ticker: INKT
Reported as of: 02 Jan 2026
Net transaction value: +$349,991
SEC form: 4
Accepted by SEC: 06 Jan 2026, 17:27:03 UTC
Prior SEC filing: 03 Oct 2025
Next SEC filing: 28 Apr 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Austin Charette, Attorney-in-Fact

Key filing fact

Jennifer Buell filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 06 Jan 2026.

Key facts

This page summarizes Jennifer Buell's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 17:27.

Change

Previous filing in this sequence was filed on 03 Oct 2025.
Current net transaction value: +$349,991.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001711184 Primary reporting owner

Buell Jennifer

Relationship: Chief Executive Officer
Address: 149 FIFTH AVENUE, SUITE 500, NEW YORK
Signature: By: /s/ Austin Charette, Attorney-in-Fact
Signature date: 06 Jan 2026

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INKT transaction

Common Stock

Award

Transaction value: $349,991
Shares: +31,474
Change %: +86%
Price: $11.12
Shares after: 67,966
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $11.12
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Reflects the executive's 2025 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on February 2, 2026.

Footnote F2

$11.12 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 2, 2026, the stock issuance date.

Footnote F3

The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter.